(2R,3S,5R)-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: (2R,3S,5R)-2-[6-(dimethylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• 化学式: C₁₂H₁₇N₅O₄
• 分子量: 295.29
• InChiKey: WVGPGNPCZPYCLK-WURNFRPNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.58
• 拓扑面积：
  117
• 氢给体数：
  3
• 氢受体数：
  8

文献信息

• N6,N6-dimethyladenosine for use in treating or preventing primary and metastatic breast cancer
  申请人：Institut Univ. de Ciència i Tecnologia, S.A.

  公开号：EP2711008A1

  公开（公告）日：2014-03-26

  The present invention relates to the field of biotechnology. The present invention relates to a compound of formula (I), namely N6,N6-dimethyladenosine, for use in the treatment or prevention of primary and metastatic breast cancer. The present invention also relates to a combination of a compound of formula (I) with at least one further compound for use in the treatment or prevention of primary and metastatic breast cancer. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) or the combination.

  本发明涉及生物技术领域。本发明涉及一种用于治疗或预防原发性和转移性乳腺癌的式 (I) 化合物，即 N6,N6-二甲基腺苷。本发明还涉及一种式（I）化合物与至少另一种化合物的组合物，用于治疗或预防原发性和转移性乳腺癌。本发明还涉及一种包含式（I）化合物或组合物的药物组合物。
• 4-Aminopyrazolo[3,4-d]pyrimidine for use in treating or preventing primary and metastatic breast and prostate cancer
  申请人：Institut Univ. de Ciència i Tecnologia, S.A.

  公开号：EP2711007A1

  公开（公告）日：2014-03-26

  The present invention relates to the field of biotechnology. The present invention relates to 4-aminopyrazolo[3,4-d]pyrimidine, i.e. a compound of formula (I) for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention also relates to a combination of a compound of formula (I) with at least one further compound for use in the treatment or prevention of primary and metastatic breast and prostate cancer. The present invention further relates to a pharmaceutical composition comprising the compound of formula (I) or the combination.

  本发明涉及生物技术领域。本发明涉及 4-氨基吡唑并[3,4-d]嘧啶，即用于治疗或预防原发性和转移性乳腺癌和前列腺癌的式 (I) 化合物。本发明还涉及一种式（I）化合物与至少另一种化合物的组合物，用于治疗或预防原发性和转移性乳腺癌和前列腺癌。本发明还涉及一种包含式（I）化合物或组合物的药物组合物。
• PROFILING CHEMICALLY MODIFIED DNA/RNA UNITS FOR DISEASE AND CANCER DIAGNOSIS
  申请人：THE RESEARCH FOUNDATION FOR THE STATE UNIVERSITY OF NEW YORK

  公开号：US20170044619A1

  公开（公告）日：2017-02-16

  The present invention relates to high-throughput methods comprising direct infusion electrospray ionization mass spectrometry (ESI-MS), multistep tandem mass spectrometry (MS n ), consecutive reaction monitoring (CRM), ion mobility spectrometry mass spectrometry (IMS-MS), high-resolution MS, and IMS-MS, for genome-wide (whole cell or tissue) profiling of DNA and RNA nucleotides/nucleosides having a wide variety of variant structural modifications. In particular, these methods are contemplated for providing a specific profile of variant DNA and/or RNA chemically modified nucleic acids (i.e. structures) associated with specific medical conditions. Medical conditions may include, but are not limited to: cancer; including prostate, lung, uterus, larynx, ovary, breast, kidney, and many other types of cancers; specific stages of cancer; bacterial infections; viral infections; genetic and metabolic disorders; and any condition involving changes in DNA and/or RNA structural modifications.